Myelodysplastic Syndrome Clinical Trial
A Study of Engineered Donor Grafts (Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Summary
This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Eligibility Criteria
Key Inclusion Criteria:
Recipients must meet all of the following criteria:
Patients must diagnosed with one of the following histopathologically confirmed diseases, for which a myeloablative hematopoietic stem cell transplant (HCT) is planned:
acute myeloid, lymphoid or mixed phenotype leukemia that is not in CR/CRi [Ages 18-65]
myelodysplastic syndromes with > 10% to < 20% bone marrow blast burden [Ages 18-65]
acute myeloid, lymphoid or mixed phenotype leukemia that is in CR/CRi but is categorized as DRI very high risk [Ages 18-65]
Myelofibrosis [Ages 18-65]
Blastic Plasmacytoid Dendritic Cell Neoplasm [Ages 18-65]
acute myeloid, lymphoid, mixed phenotype leukemia or myelodysplastic syndromes (therapy-related/secondary MDS or eligible for alloHCT per 2017 International Expert Panel) that are in CR and intermediate to high risk per the DRI in patients aged 66 to 75 [Ages 66-75]
chronic myeloid leukemia that is in chronic phase with history of blast crisis or accelerated phase and/or is resistant to or intolerant of >1 first- or second-generation TKI [Ages 18-65]
Patients must be matched to a 8/8 HLA-matched related or unrelated donor
Estimated glomerular filtration rate (eGFR) > 50 mL/minute
Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)
Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded) and ALT/AST < 3 times ULN
Key Exclusion Criteria:
Recipients meeting any of the following exclusion criteria will not be eligible:
History of prior allogeneic HCT
Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
Pre-planned donor lymphocyte infusion (DLI)
Planned pharmaceutical in vivo or ex vivo T cell depletion
Positive for anti-donor HLA antibodies against an allele in the selected donor
Karnofsky performance score < 70%
Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4
Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
Seropositive for HIV-1 or -2 antibody, HTLV-1 or -2 antibody, Hepatitis B sAg, or Hepatitis C antibody
Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected
Women who are pregnant or breastfeeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 20 Locations for this study
Los Angeles California, 90095, United States More Info
Contact
Miami Florida, 33136, United States More Info
Contact
Atlanta Georgia, 30322, United States More Info
Contact
Kansas City Kansas, 66160, United States
New York New York, 10021, United States More Info
Contact
New York New York, 10065, United States More Info
Contact
Portland Oregon, 97239, United States More Info
Contact
Nashville Tennessee, 37203, United States More Info
Contact
Nashville Tennessee, 37232, United States More Info
Contact
Houston Texas, 77054, United States
San Antonio Texas, 78229, United States
Salt Lake City Utah, 84112, United States More Info
Contact
How clear is this clinincal trial information?